CJC-1295 with DAC 5mg

Manufacturer: Sinoway

Pharmaceutical name: Drug Affinity Complex: Growth Hormone-Releasing Factor

Pack: 1 vial (5 mg)

CJC-1295 peptide with DAC, also referred to as DAC:GRF, is a synthetic counterpart of a segment of naturally occurring growth hormone releasing hormone (GHRH). The chemical structure of CJC-1295 with DAC is centered around the first 29 amino acids of endogenous GHRH, as these initial amino acids are essential for full biological function.

 

Nonetheless, this peptide has been further enhanced by altering four amino acids to improve its stability and effectiveness compared to the earlier version of CJC-1295 without DAC. These modifications enable the peptide to permanently attach to the protein albumin within the body, thereby decreasing degradation and oxidation to enhance its stability. Additionally, these extra amino acids boost the peptide's binding affinity to the GHRH receptor, which increases its effectiveness. GHRH is crucial for the natural secretion of growth hormone and is necessary for optimal natural growth during development.

 

CJC-1295 functions by promoting growth hormone release through its interaction with GHRH receptors and should trigger the secretion of a range of growth hormone peptides typically released by the pituitary gland. These hormones can lead to improvements in bone density and collagen production, as well as strengthen the immune system. They also aid in increasing lean muscle mass.

 

CJC-1295 with DAC can be used in conjunction with growth hormone releasing peptides to enhance the results of peptide cycling. This combination is often paired with growth hormone replacement peptides (GHRP) 6 or GHRP-2. Using CJC-1295 DAC alongside GHRPs can expedite fat loss and weight reduction while promoting anabolic effects through growth hormone-induced fat breakdown. Overall, CJC-1295 with DAC enhances protein synthesis and supports the development of lean muscle tissue. The peptide also facilitates quicker recovery from injuries, reduces body fat, and promotes increased muscle mass. Additionally, the growth-promoting attributes of CJC-1295 DAC stimulate cell growth and division, contributing to improved skin health, healing, and immune system performance.

 

This peptide should not be confused with CJC-1295 without DAC, as their chemical properties differ significantly, impacting dosage requirements. CJC-1295 DAC has an approximate half-life of 8 days post-injection. Injections of CJC-1295 with DAC should be administered subcutaneously and can be taken once a week at doses of either 100 mcg or 200 mcg, due to its extended half-life. This approach to cycling CJC-1295 DAC will lead to a sustained overall increase in growth hormone levels. A weekly injection of CJC-1295 with DAC can be stacked with other GHRPs, like GHRP-6 or GHRP-2.

 

Numerous studies have confirmed the growth-enhancing effects and safety of GHRH given to children with growth hormone deficiencies. Various treatment protocols, including intravenous pulses, intranasal application, subcutaneous injections, and continuous infusion, have been evaluated to demonstrate that the growth-promoting impact of GHRH is related to the dosage and frequency. No unexpected adverse reactions have been reported following extended treatment, regardless of how it was administered. However, some mild side effects may occur, such as fatigue, euphoria (a feeling of elation), water retention, tingling, and numbness. Adhering to the recommended dosages will help minimize the risk of side effects.